Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents	$ 20,729,983	$ 10,867,050
Terms of license Agreement	Belgian Volition entered into a Master License and Supply Agreement (the “License Agreement”) with Heska Corporation (“Heska”), a leading global provider of advanced veterinary diagnostics, pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q® Vet Cancer Test at the point of care (“POC”) initially for the screening of lymphoma and hemangiosarcoma in dogs (“Canine Lymphoma & HSA”), and non-exclusive rights to sell its Nu.Q® Vet Cancer Test in kit format (“Kits”) through Heska’s network of central reference laboratories (“Central Lab”) initially for Canine Lymphoma & HSA
Initial term for POC	22 years
Initial term for Central Lab	5 years
Upfront payment	$ 13,000,000.0	10,000,000.0
Milestone amount recognized	28,000,000.0
Deferred revenue	23,000,000.0
Amount in excess of FDIC limit	15,220,237	7,925,876
Accumulated other comprehensive loss	243,940	227,097
Research and development expenses	19,600,000	15,300,000
Impairment losses	0	0
Accounts receivable	$ 242,617	72,609
Concentration of credit risk	65.00%
Heska Corporation [Member]
Deferred revenue	$ 23,000,000.0	$ 10,000,000.0
Warrants And Options [Member]
Potentially dilutive securities excluded from the computation of EPS	9,197,021	7,787,013
Belgian Deposit Guarantee [Member]
Deposits/cash in excess of insured limits	$ 4,227,147	$ 1,725,981
Singapore Deposit Insurance [Member]
Deposits/cash in excess of insured limits	107,349	100,601
UK Deposit Protection Scheme [Member]
Deposits/cash in excess of insured limits	$ 320,124	$ 326,631